Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Gateway for Cancer Research will commence phase II study of metastatic colorectal cancer using ADAPT therapy based on a 2010 AACR presentation.
Subscribe to our email newsletter
Led by Edward Lin,a medical oncologist at the University of Washington and his collaborators, the study will be the first to specifically target colon cancer stem cells.
The study will apply a combination drug therapy of Capecitabine (a chemotherapy drug) and Celecoxib (an FDA approved arthritis medication)in treating colon cancer stem cells.
Edward Lin said the treatment is offering an immediate benefit to today’s cancer patients.
”95% of participants are out and about in their daily lives, doing what they need to do without skipping a beat,"Lin added.
"The Gateway has provided seed funding that will help this study continue and hopefully help the vision expand so the treatment is available to many more patients."
Out of 124 treated patients, 40% of those treated with this protocol have achieved good progress.